Mylan

OGIVRI

View Prices
  1. Home
    2.  / 
  2. Q Code
    3.  / OGIVRI – Q5114

Manufacturer:

Mylan

Name:

OGIVRI

HCPCS Code Descriptor:

Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg

Category:

Q Code

HCPCS:

Q5114

NDC(s):

67457-0991-15, 67457-0847-44

Primary Type:

Oncology Biosimilar

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

OGIVRI is an Oncology Biosimilar drug manufactured by Mylan and administered via the Intravenous route of administration. The Q Code: Q5114 is aligned to the drug OGIVRI.

Ogivri (trastuzumab) is a cancer drug that targets the HER2 protein in cancer cells. This medication can be used to treat specific types of breast and stomach cancers. Ogivri can be used in combination with other cancer medications. Ogivri is manufactured by Mylan instituitional and is biosimilar to the medication Herceptin (J9356). Ogivri has been aligned to the HCPCS code Q5114 since July 2019. Patient assistance programs for this medication can be found through Viatris Patient Assistance.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

7/1/19

HCPCS Effective Date:

7/1/19

HCPCS Short Description:

Inj ogivri 10 mg

Billing and Coding Guide:

https://www.viatrisadvocate.com/-/media/viatrisadvocatecom/pdf/ogiviri/tra-2019-0102-v2-coding-and-billing-guide-for-ogivri.pdf?la=en

Patient Assistance:

https://www.viatris.com/en-us/lm/united-states/patient-assistance-program

OGIVRI - Q5114